Quick Answer
ClearPoint Neuro, Inc. reported Diluted EPS of $0.90 per share (loss) for fiscal year 2025.
ClearPoint Neuro, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.90 | -28.6% |
| 2024 | -$0.70 | +22.2% |
| 2023 | -$0.90 | -32.4% |
| 2022 | -$0.68 | +1.4% |
| 2021 | -$0.69 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.21 | -16.7% | +0.0% |
| June 30, 2025 | -$0.21 | -31.2% | +4.5% |
| March 31, 2025 | -$0.22 | -37.5% | -22.2% |
| September 30, 2024 | -$0.18 | +10.0% | -12.5% |
| June 30, 2024 | -$0.16 | +44.8% | +0.0% |
| March 31, 2024 | -$0.16 | +30.4% | +20.0% |
| September 30, 2023 | -$0.20 | -33.3% | +31.0% |
| June 30, 2023 | -$0.29 | -61.1% | -26.1% |
- ClearPoint Neuro, Inc. showed a decrease of -28.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, ClearPoint Neuro, Inc.’s diluted eps has declined by 30.4% (from $0.69 per share (loss) to $0.90 per share (loss)).
- The most recent figure is from ClearPoint Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: